AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35271609 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 175
Study 35271609 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1, 3, and 5 measurements of copeptin and MR‐proADM
Number of subjects: 175
Study 33296560 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices (drug-coated-device group)
Number of subjects: 2289
Study 33296560 — intervention group
Group type: COMPARATOR
Intervention: Uncoated devices (uncoated-device group)
Number of subjects: 2289
Study 34891224 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 359
Study 34891224 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 359
Study 33249735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose
Number of subjects: 27
Study 33249735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose
Number of subjects: 27
Study 33249735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose + 60 ppm lactisole
Number of subjects: 27
Study 33249735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose + 60 ppm lactisole
Number of subjects: 27
Study 32102644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 420
Study 32102644 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 420
Study 34313595 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement Facilitation Intervention (EFI) + myCompass 2
Number of subjects: 849
Study 34313595 — intervention group
Group type: COMPARATOR
Intervention: myCompass 2 alone
Number of subjects: 849
Study 34313595 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 849
Study 34313595 — intervention group
Group type: EXPERIMENTAL
Intervention: myCompass 2
Number of subjects: 849
Study 33648377 — intervention group
Group type: EXPERIMENTAL
Intervention: A0 pulley release
Number of subjects: 24
Study 33648377 — intervention group
Group type: EXPERIMENTAL
Intervention: A1 pulley release
Number of subjects: 24
Study 33648377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both A0 and A1 pulley release
Number of subjects: 24
Study 33648377 — intervention group
Group type: COMPARATOR
Intervention: Initial A1 release
Number of subjects: 24
Study 33648377 — intervention group
Group type: COMPARATOR
Intervention: Initial A0 release
Number of subjects: 24
Study 33559445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needling stripping after local anesthesia
Number of subjects: 900
Study 33559445 — intervention group
Group type: COMPARATOR
Intervention: Fire needling
Number of subjects: 900
Study 33559445 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 900
Study 36261757 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium sodium hydrogen citrate (PSHC)
Number of subjects: 34
Study 36261757 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 34
Study 34469668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder Training + Intravaginal Electrical Stimulation (BT+IVES)
Number of subjects: 62
Study 34469668 — intervention group
Group type: COMPARATOR
Intervention: Bladder Training (BT)
Number of subjects: 62
Study 32720852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double elastic band in the frontal plane
Number of subjects: 21
Study 32720852 — intervention group
Group type: COMPARATOR
Intervention: Single elastic band in the frontal plane
Number of subjects: 21
Study 32720852 — intervention group
Group type: EXPERIMENTAL
Intervention: Double elastic band in the scapular plane
Number of subjects: 21
Study 36442036 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the left DLPFC (n = 27)
Number of subjects: 103
Study 36442036 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the left DLPFC (n = 27)
Number of subjects: 103
Study 36442036 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the right DLPFC (n = 25)
Number of subjects: 103
Study 36442036 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the right DLPFC (n = 24)
Number of subjects: 103
Study 33938630 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbera™ fluid‐filled intragastric balloon (IGB)
Number of subjects: 26
Study 32812663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing niosomes loaded with 1% w/v purple glutinous rice extract
Number of subjects: 20
Study 35675854 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (24 Gy in 2 fractions)
Number of subjects: 137
Study 35675854 — intervention group
Group type: COMPARATOR
Intervention: cEBRT (20 Gy in 5 fractions)
Number of subjects: 137
Study 35675854 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 137
Study 35675854 — intervention group
Group type: COMPARATOR
Intervention: cEBRT
Number of subjects: 137
Study 34044454 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2609
Study 34044454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2609
Study 32702925 — intervention group
Group type: EXPERIMENTAL
Intervention: With drainage (WD group)
Number of subjects: 123
Study 32702925 — intervention group
Group type: COMPARATOR
Intervention: Without drainage (WOD group)
Number of subjects: 123
Study 34027754 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game-based training
Number of subjects: 66
Study 34027754 — intervention group
Group type: COMPARATOR
Intervention: Motor-cognitive dual-task training
Number of subjects: 66
Study 34027754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 34166648 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 mg levonorgestrel intrauterine system (IUS)
Number of subjects: 518
Study 34166648 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mm(2) copper IUD
Number of subjects: 518
Study 35579384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 0
Study 35579384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 0
Study 34175829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern 3 C-peptide trajectory (undetectable at 12 and 24 weeks, detectable at 34 weeks)
Number of subjects: 127
Study 34175829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern 3 C-peptide trajectory
Number of subjects: 127
Study 34175829 — intervention group
Group type: COMPARATOR
Intervention: Pattern 1 C-peptide trajectory (undetectable throughout pregnancy)
Number of subjects: 127
Study 34251865 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted case management intervention
Number of subjects: 113
Study 34251865 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 113
Study 33146332 — intervention group
Group type: EXPERIMENTAL
Intervention: BioRaCe system
Number of subjects: 47
Study 33146332 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc system
Number of subjects: 47
Study 35027169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (70 L min−1)
Number of subjects: 80
Study 35027169 — intervention group
Group type: COMPARATOR
Intervention: Facemask Oxygen (15 L min−1)
Number of subjects: 80
Study 35027169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen
Number of subjects: 80
Study 33609102 — intervention group
Group type: EXPERIMENTAL
Intervention: CuBlock normalization algorithm
Number of subjects: 0
Study 33609102 — intervention group
Group type: COMPARATOR
Intervention: ComBat, UPC, YuGene, DBNorm, Shambhala, simple log2 transform
Number of subjects: 0
Study 32715556 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal gel (25 μg, 2 mL applied intravaginally daily for 2 weeks, then two doses per week for 6 weeks)
Number of subjects: 80
Study 32715556 — intervention group
Group type: COMPARATOR
Intervention: Control group (K‐Y® Jelly)
Number of subjects: 80
Study 32715556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Estradiol and Control)
Number of subjects: 80
Study 32715556 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal gel and Control group
Number of subjects: 80
Study 35503997 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium ferric gluconate complex (SFGC) 125 mg per day for 3-5 days
Number of subjects: 34
Study 35503997 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium ferric gluconate complex (SFGC)
Number of subjects: 34
Study 33977743 — intervention group
Group type: EXPERIMENTAL
Intervention: SHT intervention
Number of subjects: 94
Study 33977743 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (Control)
Number of subjects: 94
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain frame
Number of subjects: 413
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss frame
Number of subjects: 413
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain outcome
Number of subjects: 413
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain outcome
Number of subjects: 413
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency number format
Number of subjects: 413
Study 33499677 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage number format
Number of subjects: 413
Study 33688840 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based cognitive behavioral therapy (CBT-M) combined with standard psychiatric care (n=22)
Number of subjects: 45
Study 33688840 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric care alone (n=23)
Number of subjects: 45
Study 34736367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658
Study 34736367 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study 34493219 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education booklet
Number of subjects: 0
Study 32784162 — intervention group
Group type: EXPERIMENTAL
Intervention: Causse Loop Piston
Number of subjects: 148
Study 32784162 — intervention group
Group type: COMPARATOR
Intervention: Big Easy Piston
Number of subjects: 148
Study 35414614 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group exposed to 3D natural videos with calm Quran or music voices via phone using VR glasses immediately after anesthesia until completion of skin suture
Number of subjects: 351
Study 35414614 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine hospital care
Number of subjects: 351
Study 35414614 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 351
Study 33782992 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 118
Study 33782992 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 118
Study 32436277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 42
Study 32436277 — intervention group
Group type: COMPARATOR
Intervention: Resting state control condition
Number of subjects: 42
Study 33944622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) at a starting dose of 0.5 mg/kg/day, titrated to 1.2 mg/kg/day
Number of subjects: 100
Study 33944622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 100
Study 33944622 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs) (n=80)
Number of subjects: 100
Study 34331964 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h fasting
Number of subjects: 20
Study 34331964 — intervention group
Group type: COMPARATOR
Intervention: 12-h fasting
Number of subjects: 20
Study 34331964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (both 12-h and 24-h)
Number of subjects: 20
Study 34331964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 20
Study 33883841 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 30
Study 33883841 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 30
Study 34744060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-Ca alloy scaffold
Number of subjects: 2
Study 34744060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-Sr alloy scaffold
Number of subjects: 2
Study 33795788 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Number of subjects: 0
Study 34158437 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing and Punica granatum chip
Number of subjects: 30
Study 34158437 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing and Punica granatum gel
Number of subjects: 30
Study 34158437 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing alone
Number of subjects: 30
Study 36817351 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ALA
Number of subjects: 46
Study 36817351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 35925030 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted passive range of motion training combined with conventional rehabilitation
Number of subjects: 12
Study 32040376 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive
Number of subjects: 400
Study 32040376 — intervention group
Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 400
Study 32040376 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive and Havrix
Number of subjects: 400
Study 36096778 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nail (EIN)
Number of subjects: 28
Study 36096778 — intervention group
Group type: COMPARATOR
Intervention: Locking compression plate (LCP)
Number of subjects: 28
Study 33565686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 141
Study 33565686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 35177053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin as an add-on therapy to standard of care (SoC)
Number of subjects: 0
Study 35177053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34087201 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pipeline for extracting polyp findings and assigning surveillance intervals
Number of subjects: 324
Study 34087201 — intervention group
Group type: COMPARATOR
Intervention: Gastroenterologist determination of surveillance intervals
Number of subjects: 324
Study 33961534 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light LED therapy 2–3 times/week for 6 weeks
Number of subjects: 8
Study 33961534 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light LED therapy
Number of subjects: 8
Study 33961534 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral side)
Number of subjects: 8
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast speaking rate
Number of subjects: 38
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium speaking rate
Number of subjects: 38
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow speaking rate
Number of subjects: 38
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal loading tasks (VLTs)
Number of subjects: 38
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 38
Study 34272142 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 38
Study 34875666 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care for depression
Number of subjects: 260
Study 34875666 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 260
Study 33293656 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Treatment (HAART)
Number of subjects: 800
Study 33293656 — intervention group
Group type: COMPARATOR
Intervention: HAART naïve
Number of subjects: 800
Study 33293656 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 800
Study 35070202 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated exercise (IE)
Number of subjects: 40
Study 35070202 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33261620 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing training set size
Number of subjects: 0
Study 33261620 — intervention group
Group type: EXPERIMENTAL
Intervention: Data augmentation (traditional and domain-specific)
Number of subjects: 0
Study 33261620 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific Hounsfield unit windowing
Number of subjects: 0
Study 33261620 — intervention group
Group type: EXPERIMENTAL
Intervention: Model ensembles
Number of subjects: 0
Study 33261620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all beneficial strategies
Number of subjects: 0
Study 36200477 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 2764
Study 36200477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2764
Study 32646746 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill Running (DR)
Number of subjects: 10
Study 32646746 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill Running (UR)
Number of subjects: 10
Study 32946612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 μg of protein per dose of P pratense allergoid
Number of subjects: 0
Study 32946612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32946612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 μg of protein per dose of P pratense allergoid
Number of subjects: 0
Study 35085318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous catheter (UL PIVC)
Number of subjects: 257
Study 35085318 — intervention group
Group type: COMPARATOR
Intervention: Standard long peripheral intravenous catheter (SL PIVC)
Number of subjects: 257
Study 35085318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicant doses (1 vs 0)
Number of subjects: 257
Study 35085318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicant doses (2 vs 0)
Number of subjects: 257
Study 35085318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicant doses (≥ 3 vs 0)
Number of subjects: 257
Study 34746745 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg of Depo-Provera
Number of subjects: 60
Study 34746745 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of Depo-Provera
Number of subjects: 60
Study 34746745 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 mg of Depo-Provera
Number of subjects: 60
Study 34746745 — intervention group
Group type: COMPARATOR
Intervention: Depo-subQ provera 104
Number of subjects: 60
Study 32756843 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 kg N da‐1
Number of subjects: 3
Study 32756843 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5 kg N da‐1
Number of subjects: 3
Study 32756843 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPP blended ammonium sulphate nitrate
Number of subjects: 3
Study 32756843 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea with NBPT urease inhibitor
Number of subjects: 3
Study 32756843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen treatments
Number of subjects: 3
Study 33583462 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Minds intervention
Number of subjects: 89
Study 33583462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 34142986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program (high level: CME score 32-35; low level: CME score 28-31) with ten sessions of 45 minutes each
Number of subjects: 201
Study 34142986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cognitive stimulation program)
Number of subjects: 201
Study 32321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically diffuse disease in the left anterior descending artery (LAD)
Number of subjects: 671
Study 32321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically focal disease in the left anterior descending artery (LAD)
Number of subjects: 671
Study 32321880 — intervention group
Group type: COMPARATOR
Intervention: Non-LAD vessels
Number of subjects: 671
Study 34928698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (7000 mg)
Number of subjects: 314
Study 34928698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 32267235 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality team training
Number of subjects: 120
Study 32267235 — intervention group
Group type: COMPARATOR
Intervention: Live simulations team training
Number of subjects: 120
Study 32267235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Virtual reality and Live simulations)
Number of subjects: 120
Study 34547193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg daily
Number of subjects: 160
Study 34547193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32518039 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual fascial manipulation
Number of subjects: 19
Study 36220847 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily group: inhaled budesonide 1 mg once a day, reduced to 0.25 mg once a day after 12 weeks if well controlled, maintained until 52 weeks
Number of subjects: 474
Study 36220847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose group: inhaled budesonide 1 mg twice daily for 7 days during respiratory tract illness
Number of subjects: 474
Study 36220847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent medium-dose group: inhaled budesonide 0.5 mg twice daily until symptoms reduced or risk factors absent for 3 days
Number of subjects: 474
Study 36220847 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 474
Study 33533309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher narcissism levels
Number of subjects: 332
Study 32930113 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanglaite (KLT) injection combined with gefitinib
Number of subjects: 554
Study 32930113 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 554
Study 34767481 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges to clinicians prompting Serious Illness Conversations (SICs)
Number of subjects: 14607